Magnetic Resonance (MR) Spectroscopy of Breast Cancer Tissue

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2014 by Norwegian University of Science and Technology
Sponsor:
Collaborators:
The Research Council of Norway
The Norwegian Women´s Public Health Association
Information provided by (Responsible Party):
Norwegian University of Science and Technology
ClinicalTrials.gov Identifier:
NCT00184210
First received: September 12, 2005
Last updated: May 22, 2014
Last verified: May 2014
  Purpose

Breast cancer tissue is collected from women undergoing scheduled surgery for breast cancer. The tissue specimen are analyzed by MR spectroscopy. After MR, the intact tissue specimen can be analyzed by other methods, such as histopathology.

The MR spectral profiles are compared to clinical findings such as the patients diagnosis, lymph node status and tumor size.


Condition
Breast Neoplasms

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: HR MAS MR Spectroscopy of Breast Cancer Tissue

Resource links provided by NLM:


Further study details as provided by Norwegian University of Science and Technology:

Primary Outcome Measures:
  • MRimage of breast cancer tissue [ Time Frame: 0 hour ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

tissue


Estimated Enrollment: 1000
Study Start Date: January 2000
Estimated Study Completion Date: December 2020
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

women in surgery for breast cancer

Criteria

Inclusion Criteria:

  • Palpable breast cancer lesion
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00184210

Contacts
Contact: Beathe Sitter, PhD +47 73 55 13 53 beathesi@ntnu.no
Contact: Tone F Bathen, PhD +47 73 86 38 44 tone.bathen@ntnu.no

Locations
Norway
Norwegian University of Technology and Science Recruiting
Trondheim, Norway, 7491
Contact: Beathe Sitter, PhD    +47 73 55 13 53    beathesi@ntnu.no   
Sponsors and Collaborators
Norwegian University of Science and Technology
The Research Council of Norway
The Norwegian Women´s Public Health Association
Investigators
Study Chair: Ingrid S Gribbestad, PhD Norwegian University of Technology and Science
  More Information

Publications:
Responsible Party: Norwegian University of Science and Technology
ClinicalTrials.gov Identifier: NCT00184210     History of Changes
Other Study ID Numbers: 154080/I30
Study First Received: September 12, 2005
Last Updated: May 22, 2014
Health Authority: Norway: Norwegian Social Science Data Services

Keywords provided by Norwegian University of Science and Technology:
Magnetic Resonance Spectroscopy

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases

ClinicalTrials.gov processed this record on September 16, 2014